ENTA · Enanta Pharmaceuticals Inc
$13.18
+0.54 (+4.27%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$346.01M
Shares
29.13M
Volume · Sep 30
425.88K
Avg daily vol (3M)
218.17K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.18
Open$12.67
Day$12.44–13.41
52W close$10.33–16.85
Avg vol 30d263K
Short int2.6M · 8.9% float · 10.7d
Short vol42%
Last earningsNov 25, 2024
DataJan 2020–Sep 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
call held May 6, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$65.26M
Trailing 12 months
Net income (TTM)
−$63.23M
Trailing 12 months
Revenue growth YoY
-21.6%
Year over year
Operating margin
-90.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.1%
Year over year · more shares
Price change (1Y)
-16.6%
Trailing year
Short interest
8.9%
Latest settlement · 10.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
+1%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
44%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−6%
trailing
YTD return
−16%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $14 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.93% of float · ▼ -0.6% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
122 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-32.2M
Quant / Vol
risk profile
Volatility
50%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed May 6, 2020
HCV sales
· calendar 2020
$2.3B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
+1%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
44%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $13 › 200d $14 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.93% of float · ▼ -0.6% MoM · 10.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
122 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $10
Now $13 · 44%
Range high $17
vs 200-day avg -2%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and short-term and long-term marketable securities | $211.5M | fiscal third quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTA
this stock
Enanta Pharmaceuticals Inc
|
$346.01M | -16.4% | +16.5% | — | 8.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTA | +10.3% | -2.4% | -5.5% | -1.1% | -16.4% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +11.0% | -2.6% | -17.7% | -0.6% | -28.3% |